Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats

Journal of Toxicological Sciences

Volumn 33, Issue 4, 2008, Pages 447-457

  Kishida, Tomoyuki ^a   Muto, Shin Ichi ^a   Hayashi, Morimichi ^a   Tsutsui, Masaru ^a   Tanaka, Satoru ^a   Murakami, Makoto ^a   Kuroda, Junji ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cytochrome P450; Induction; Nuclear receptor; Sprague Dawley rat; Strain difference; Wistar rat

Indexed keywords

ANDROSTANE DERIVATIVE; ANDROSTANE RECEPTOR; CYTOCHROME P450 1A; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C; CYTOCHROME P450 2C6; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE; MESSENGER RNA; PHENOBARBITAL; PREGNANE X RECEPTOR; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

RATTUS; RATTUS NORVEGICUS;

EID: 55949134723     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.33.447     Document Type: Article

References (37)

1. Aoyama, H., Kikuta, M., Shirasaka, N., Hojo, H., Takahashi, K.L., Shimizu, N., Harigae, M., Taguchi, F. and Teramoto, S. (2002): Historical control data on reproductive abilities and incidences of spontaneous fetal malformations in Wistar Hannover GALAS rats. Congenital Anomalies, 42, 194-201.
2. Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P. and Berkenstam, A. (1998): Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. PNAS, 95, 12208-12213.
3. Blumberg, B., Sabbagh, W.Jr., Juguilon, H., Bolado, J.Jr., van Meter, C.M., Ong, E.S. and Evans, R.M. (1998): SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev., 12, 3195-3205.
4. Burke, M.D., Thompson, S., Weaver, R.J., Wolf, C.R. and Mayers, R.T. (1994): Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol., 48, 923-936.
5. Cameron, R., Sharma, R.N., Sweeney, G.D., Farber, E. and Murray, R.K. (1976): A novel electrophoretic pattern of induction of rat liver microsomal membrane polypeptides by 2-acetylaminofluorene, nitrosamine and azo dye administration. Biochem. Biophys. Res. Commun., 71, 1054-1061.
6. Cui, X., Thomas, A., Montgomery, D., Gu, C., Morrison, R.A., White, R.E. and Cheng, K.C. (2005): Rat PXR reporter-gene activity correlates with the induction of CYP3A in rat precision-cut liver slices. Comb. Chem. High Throughput Screening, 8, 341-346.
7. Degawa, M., Tanimura, S., Agatsuma, T. and Hashimoto, Y. (1989): Hepatocarcinogenic heterocyclic aromatic amines that induce cytochrome P-448 isozymes, mainly cytochrome P-448H (P-450IA2), responsible for mutagenic activation of the carcinogens in rat liver. Carcinogenesis, 10, 1119-1122.
8. Eiben, R. and Bomhard, E.M. (1999): Trends in mortality, body weights and tumor incidences of Wistar rats over 20 years. Exp. Toxicol. Pathol., 51, 523-536.
9. Ganem, L.G. and Jefcoate, C.R. (1998): Endocrine factors modulate the phenobarbital-mediated induction of cytochromes P450 and phase II enzymes in a similar strain-dependent manner. Toxicol. Appl. Pharmacol., 150, 68-75.
10. Grasso, P. and Hinton, R.H. (1991): Evidence for and possible mechanisms of non-genotoxic carcinogenesis in rodent liver. Mutat. Res., Fundam. Mol. Mech. Mutagen., 248, 271-290.
11. Guengerich, F.P. (1988): Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res., 48, 2946-2954.
12. Hakura, A., Suzuki, S. and Satoh, T. (1999): Advantage of the use of human liver S9 in the Ames test. Mutat. Res., Genet. Toxicol. Environ. Mutagen., 438, 29-36.
13. Hino, O., Nemoto, N., Nagao, M., Kosugi, A. and Kitagawa, T. (1982): Induction of drug-metabolizing enzymes in rat liver by 3′-methyl-4- (dimethylamino)azobenzene. Cancer Lett., 15, 131-136.
14. Hissink, A.M., Oudshoorn, M.J., Van Ommen, B. and Van Bladeren, P.J. (1997): Species and strain differences in the hepatic cytochrome P450-mediated biotransformation of 1,4-Dichlorobenzene. Toxicol. Appl. Pharmacol., 145, 1-9.
15. Honkakoski, P. and Negishi, M. (2000): Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J., 347, 321-327.
16. Imaoka, S., Terano, Y. and Funae, Y. (1989): Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats. J. Biochem., 105, 939-945.
17. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moore, J.T. and Kliewer, S.A. (1998): The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 102, 1016-1023.
18. Lin, J.H. (2006): CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm. Res., 23, 1089-1116.
19. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951): Protein measurements with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
20. Martinez, M.N. and McGilveray, I. (2003): AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns. AAPS Pharm. Sci., 5, 1-22.
21. Masubuchi, Y., Hosokawa, S., Horie, T., Suzuki, T., Ohmori, S., Kitada M. and Narimatsu, S. (1994): Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes: the role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos., 22, 909-915.
22. Meredith, C., Scott, M.P., Renwick, A.B., Price, R.J. and Lake, B.G. (2003): Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices. Xenobiotica, 33, 511-527.
23. Nedelcheva, V., Gut, I., Souček, P. and Frantík, E. (1998): Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2-and 1,4-dichlorobenzene in rat, mouse and human liver microsomes. Chem.-Biol. Interact., 115, 53-70.
24. Nelson, D.R., Koyamans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman, D.J., Waterman, M.R., Gotoh, O., Coon, M.J., Estabrook, R.W., Gunsalus, I.C. and Nebert, D.W. (1996): P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
25. Okey, A.B., Riddick, D.S. and Harper, P.A. (1994): The Ah receptor: mediator of the toxicity of 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Lett., 70, 1-22.
26. Omura, T. and Sato, R. (1964): The carbon monoxide-binding pigment of liver microsomes. I.Evidence for its hemoprotein nature. J. Biol. Chem., 239, 2370-2378.
27. Pettersen, J.C., Morrissey, R.L., Saunders, D.R., Pavkov, K.L., Luempert, L.G.3rd, Turnier, J.C., Matheson, D.W. and Schwartz, D.R. (1996): A 2-year comparison study of Crl:CD BR and Hsd: Sprague-Dawley SD rats. Fundam. Appl. Toxicol., 33, 196-211.
28. Poland, A., Glover, E. and Kende, A.S. (1976): Stereospecific, high affinity binding of 2,3,7,8,-terachlorodibenzo-p-dioxin by hepatic cytosol: evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem., 251, 4936-4946.
29. Sakuma, T., Ohtake, M., Katsurayama, Y., Jarukamjorn, K. and Nemoto, N. (1999): Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. Drug Metab. Dispos., 27, 379-384.
30. Saito, K., Sakai, N., Kim, H.S., Ishizuka, M., Kazusaka, A. and Fujita, S. (2004): Strain differences in diazepam metabolism at its three metabolic sites in sprague-dawley, brown Norway, dark agouti, and Wistar strain rats. Drug Metab. Dispos., 32, 959-965.
31. Sato, M., Yoshida, T., Suzuki, Y., Degawa, M. and Hashimoto, Y. (1981): Selective induction of microsomal 2-acetylaminofluorene N-hydroxylation by dietary 2-acetylaminofluorene in rats. Carcinogenesis, 2, 571-574.
32. Studenberg, S.D. and Brouwer, K.L.R. (1991): Phenacetin and acetaminophen metabolism in the isolated perfused rat liver: precursor concentration influences the selection of kinetic parameters to assess hypoxic impairment. Drug Metab. Dispos., 19, 423-429.
33. Uetrecht, J.P. (2003): Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today., 8, 832-837.
34. Vyhlidal, C.A., Gaedigk, R. and Leeder, J.S. (2005): Nuclear receptor expression in fetal and pediatric liver: Correlation with CYP3A expression. Drug Metab. Dispos., 34, 131-137.
35. Xie, W., Barwick, J.L., Simon, C.M., Pierce, A.M., Safe, S., Blumberg, B., Guzelian, P.S. and Evans, R.M. (2000): Reciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev., 14, 3014-3023.
36. Waxman, D.J. and Azaroff, L. (1992): Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J., 281, 577-592.
37. Yoshikawa, K., Nohmi, T., Miyata, R., Ishidate, M.Jr., Ozawa, N., Isobe, M., Watabe, T., Kada, T. and Kawachi, T. (1982): Differences in liver homogenates from Donryu, Fischer, Sprague-Dawley and Wistar strains of rat in the drug-metabolizing enzyme assay and the Salmonella/hepatic S9 activation test. Mutat. Res., Fundam. Mol. Mech. Mutagen., 96, 167-186.